---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-000953"
form_type: "8-K"
ticker: "CTOR"
cik: "0001851484"
company_name: "CITIUS ONCOLOGY, INC."
filed_at: "2025-01-06T23:59:59+00:00"
generated_at: "2026-05-28T11:26:43.979991+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Citius Oncology retains Jefferies to explore strategic alternatives including sale or licensing

## Summary
- Jefferies LLC appointed as exclusive financial advisor to assist in evaluating strategic alternatives.
- Alternatives under consideration include partnerships, joint ventures, mergers, acquisitions, and licensing.
- Company is preparing to launch LYMPHIR, FDA-approved for relapsed/refractory Stage I-III cutaneous T-cell lymphoma.
- No timeline set; no assurance that a transaction will result from the review process.

## SEC filing metadata
- accession: 0001213900-25-000953
- form_type: 8-K
- ticker: CTOR
- cik: 0001851484
- company_name: CITIUS ONCOLOGY, INC.
- filed_at: 2025-01-06T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1851484/000121390025000953/0001213900-25-000953-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1851484/000121390025000953/ea0226665-8k_citius.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-000953
- JSON: https://secwatch.observer/filing/0001213900-25-000953.json
- Plain text: https://secwatch.observer/filing/0001213900-25-000953.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.